D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $25.00 target price on the stock. D. Boral Capital’s price objective indicates a potential upside of 455.56% from the company’s current price.

Other analysts also recently issued reports about the company. Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. BTIG Research reissued a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. Piper Sandler set a $6.00 price target on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Humacyte in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $13.00.

Humacyte Trading Up 0.2 %

Shares of HUMA stock opened at $4.50 on Thursday. Humacyte has a fifty-two week low of $2.43 and a fifty-two week high of $9.97. The firm’s 50 day moving average price is $5.31 and its two-hundred day moving average price is $6.19. The stock has a market cap of $566.37 million, a price-to-earnings ratio of -3.35 and a beta of 1.47. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Insider Activity

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the sale, the director now owns 3,677,262 shares in the company, valued at $23,350,613.70. The trade was a 8.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Laura E. Niklason sold 811,172 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,584,153 shares of company stock worth $13,476,796. 11.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Humacyte

Several institutional investors have recently made changes to their positions in HUMA. Endowment Wealth Management Inc. grew its stake in Humacyte by 3.1% during the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after buying an additional 3,000 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Humacyte in the 2nd quarter worth about $28,000. Private Advisor Group LLC lifted its position in Humacyte by 1.8% in the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after purchasing an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Humacyte by 32.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after purchasing an additional 8,557 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares during the last quarter. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.